Publications by authors named "Louise Garside"

Article Synopsis
  • Cabotegravir plus rilpivirine (CAB + RPV) is an effective long-acting injectable treatment for maintaining HIV-1 virologic suppression, and this analysis looked at its effects based on participants' body mass index (BMI).
  • Data was collected from various trials over periods ranging from 48 to 152 weeks, focusing on virologic outcomes, confirmed failures, and safety across different BMI categories.
  • Results showed similar efficacy and tolerability for CAB + RPV LA in both lower and higher BMI groups, with high rates of HIV-1 RNA suppression and comparable safety profiles.
View Article and Find Full Text PDF
Article Synopsis
  • - The study examines the safety and outcomes of a long-acting HIV treatment regimen, Cabotegravir (CAB) + Rilpivirine (RPV), focusing on injection site reactions (ISRs) experienced by participants across several trials.
  • - Analysis of injection techniques from healthcare providers revealed that practices such as slow injection speed and bringing the medication to room temperature helped minimize discomfort for patients during the injection process.
  • - Overall, the injections showed good tolerability, with most ISRs being mild to moderate and lasting only a few days, indicating that the CAB + RPV regimen is a viable option for long-term HIV maintenance therapy.
View Article and Find Full Text PDF

Objectives: Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virological suppression. This post hoc analysis summarizes outcomes for Asian participants through week 96.

Methods: Data from Asian participants naive to CAB + RPV randomized to receive dosing every 4 weeks (Q4W) or every 8 weeks (Q8W) in the FLAIR (NCT02938520) and ATLAS-2M (NCT03299049) phase 3/3b studies were pooled.

View Article and Find Full Text PDF
Article Synopsis
  • Limited data on the effects of cabotegravir + rilpivirine (CAB + RPV) in pregnant women living with HIV showed 25 pregnancies after exposure, with diverse outcomes including 10 live births.
  • The study involved women who had taken CAB + RPV and then transitioned to other antiretroviral medications when they became pregnant, with ongoing monitoring of drug levels post-exposure.
  • Results indicated that drug concentrations during pregnancy were comparable to those in non-pregnant women, but there was one reported case of congenital anomaly among the live births, prompting further investigation into pregnancy safety and outcomes.
View Article and Find Full Text PDF

In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1 RNA <40 copies/mL was achieved in 163/272 (60%) Randomized Cohort (RC) participants (with 1 or 2 remaining approved fully active antiretrovirals) and 37/99 (37%) Non-randomized Cohort (NRC) participants (with 0 fully active antiretrovirals). Here we report genotypic and phenotypic analyses of HIV-1 samples from 63/272 (23%) RC participants and 49/99 (49%) NRC participants who met protocol-defined virologic failure (PDVF) criteria through Week 96.

View Article and Find Full Text PDF